

Director / PDMR / PCA Shareholding & TR-1 Notification

Belfast and London, 2 April 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, announces that on 28 March 2024, Peter Keeling, co-founder and Executive Director of Diaceutics, and Delia Keeling (Peter Keeling's spouse and a PCA), cumulatively sold 1,500,000 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of 102 pence per Ordinary Share. As a result of the sale, Peter and Delia Keeling's combined shareholding in Diaceutics is 15,752,049 Ordinary Shares representing approximately 18.60% of the Company's issued share capital.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR. The person responsible for making this announcement on behalf of the Company is Nick Roberts, Chief Financial Officer.

**Enquiries:
Diaceutics PLC**

Ryan Keeling, Chief Executive Officer
Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500
investorrelations@diaceutics.com

Stifel Nicolaus Europe Limited (Nomad & Broker)

Ben Maddison
Nick Harland
Kate Hanshaw

Tel: +44 (0)20 7710 7600

Alma Strategic Communications

Caroline Forde, Kinvara Verdon, Kieran Breheny

Tel: +44(0)20 3405 0205
diaceutics@almastrategic.com

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Peter Keeling
2 Reason for notification		
a.	Position/Status	Executive Director
b.	Initial notification/ Amendment	Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Sale				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£1.02</td> <td>750,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£1.02	750,000
Price(s)	Volume(s)					
£1.02	750,000					
d.	Date of the transaction	28 March 2024				
e.	Place of the transaction	AIM Market of the London Stock Exchange				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014						
1 Details of the person discharging managerial responsibilities/person closely associated						
a.	Name	Delia Keeling				
2 Reason for notification						
a.	Position/Status	PCA				
b.	Initial notification/ Amendment	Initial				
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Sale				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£1.02</td> <td>750,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£1.02	750,000
Price(s)	Volume(s)					
£1.02	750,000					
d.	Date of the transaction	28 March 2024				
e.	Place of the transaction	AIM Market of the London Stock Exchange				

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS				
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ⁱⁱ :		Diaceutics PLC ORD GBP0.002		
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)				
Non-UK issuer				<input type="checkbox"/>
2. Reason for the notification (please mark the appropriate box or boxes with an "X")				
An acquisition or disposal of voting rights				<input checked="" type="checkbox"/>
An acquisition or disposal of financial instruments				<input type="checkbox"/>
An event changing the breakdown of voting rights				<input type="checkbox"/>
Other (please specify) ⁱⁱⁱ :				<input type="checkbox"/>
3. Details of person subject to the notification obligation ^{iv}				
Name		Peter & Delia Keeling		
City and country of registered office (if applicable)		NA		
4. Full name of shareholder(s) (if different from 3.) ^v				
Name				
City and country of registered office (if applicable)				
5. Date on which the threshold was crossed or reached ^{vi} :		28 March, 2024		
6. Date on which issuer notified:		28 March, 2024		
7. Total positions of person(s) subject to the notification obligation				
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B) ^{vii}
Resulting situation on the date on which threshold was crossed or reached	18.60%		18.60%	
Position of previous notification (if applicable)	20.37%		20.37%	

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached				
A: Voting rights attached to shares				
Class/type of shares ISIN code (if possible)	Number of voting rights ^{ix}		% of voting rights	
	Direct (DTR5.1)	Indirect (DTR5.2.1)	Direct (DTR5.1)	Indirect (DTR5.2.1)
GB00BJQTGV64		15,752,049		18.60%
SUBTOTAL 8. A	15,752,049			

B 1: Financial Instruments according to DTR5.3.1R (1) (a)
--

Type of financial instrument	Expiration date ^x	Exercise/ Conversion Period ^{xi}	Number of voting rights that may be acquired if the instrument is exercised/converted.	% of voting rights
SUBTOTAL 8. B 1				

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)					
Type of financial instrument	Expiration date ^x	Exercise/ Conversion Period ^{xi}	Physical or cash Settlement ^{xii}	Number of voting rights	% of voting rights
SUBTOTAL 8.B.2					

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")			
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^{xiii}			
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) ^{xiv}			
Name ^{xv}	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:	
Name of the proxy holder	
The number and % of voting rights held	
The date until which the voting rights will be held	

11. Additional information ^{xvi}

Place of completion	AIM Stock Exchange, London
---------------------	----------------------------

Date of completion

28, March 2024

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHUWVWRSOUOUAR